Santé Active Edition – Synergy Pharm: Medical Writing Solutions
We have been serving the pharmaceutical industry, and more generally the scientific research community, for more than 30 years.
Every member of our team is an experienced medical writer with a PhD, and all are native English or French speakers with bilingual proficiency in French and English. We design and write medical marketing documents intended for the scientific community, healthcare professionals or the general public, as well as all the regulatory and clinical documentation required at the various stages of drug development, regardless of the therapeutic area. We also provide an editorial assistance service to support you in the publication of your research: from the correction of your article to its submission, and the drafting of responses to reviewers.
We work accurately and efficiently to meet your deadlines, while our compliance with international standards (CONSORT, ICH, etc.), systematic proofreading between medical writers, and attention to detail guarantee that your documents will be of the highest quality. Our adaptability and responsiveness lead us to develop privileged and ongoing relationships with our clients.
Each project is unique, and our team at Santé Active Edition-Synergy Pharm are on hand to adapt and respond to your requirements. Do not hesitate to contact us to discuss your needs, we are looking forward to assisting you with your projects!
Our latest news
Team meeting in Paris – 2025
The Santé Active Edition – Synergy Pharm team recently met up in Paris for a seminar focused on collaboration, knowledge sharing and team cohesion.
Read more
World Psoriasis Day 2025
What is psoriasis?
Psoriasis is a chronic immune-mediated disease affecting 125 million people worldwide. Although psoriasis commonly manifests as a skin disease, presenting with thick, scaly and sometimes itchy and painful patches on the skin, individuals with psoriasis are also at higher risk of developing serious comorbidities (e.g. psoriatic arthritis, cardiovascular disease, and diabetes) due to underlying systemic inflammation, and mental health disorders (e.g. depression and anxiety) due to the detrimental impact of the disease on quality of life (QoL) and the burden of visible skin lesions.
Since 2014, psoriasis has been recognized by the World Health Organization (WHO) as “a chronic, noncommunicable, painful, disfiguring, and disabling disease for which there is no cure“. In May 2025, the WHO declared skin diseases as a global public health priority, which brings additional consideration to affected patients and gives them hope.
Read more